OTCMKTS:NRXGQ - NephroGenex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$0.0028
Today's Range$0.0028 - $0.0028
52-Week Range$0.0020 - $0.21
Volume2,000 shs
Average Volume26,223 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.

Receive NRXGQ News and Ratings via Email

Sign-up to receive the latest news and ratings for NRXGQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Previous SymbolNASDAQ:NRX



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

NephroGenex (OTCMKTS:NRXGQ) Frequently Asked Questions

What is NephroGenex's stock symbol?

NephroGenex trades on the OTCMKTS under the ticker symbol "NRXGQ."

Has NephroGenex been receiving favorable news coverage?

Media stories about NRXGQ stock have trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. NephroGenex earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the healthcare company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the stock's share price in the near term.

What other stocks do shareholders of NephroGenex own?

Who are NephroGenex's key executives?

NephroGenex's management team includes the folowing people:
  • John P. Hamill CPA, Chief Executive Officer, Chief Financial Officer

How do I buy shares of NephroGenex?

Shares of NRXGQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NephroGenex's official website?

The official website for NephroGenex is http://www.nephrogenex.com/.

How can I contact NephroGenex?

NephroGenex's mailing address is PO Box 400, JAMISON, PA 18929-0400, United States. The healthcare company can be reached via phone at +1-609-5538887.

MarketBeat Community Rating for NephroGenex (OTCMKTS NRXGQ)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  88 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  156
MarketBeat's community ratings are surveys of what our community members think about NephroGenex and other stocks. Vote "Outperform" if you believe NRXGQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NRXGQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel